Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-06
1998-10-06
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
5361231, 53612312, 536124, A61K 31715, C07H 100, C07H 300, C08B 3700
Patent
active
058176438
ABSTRACT:
The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucan of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.-glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1.beta., TNF.alpha.) that can cause detrimental side effects, such as fever and inflammation.
REFERENCES:
patent: 4138479 (1979-02-01), Truscheit et al.
patent: 4237266 (1980-12-01), Sugiura et al.
patent: 4707471 (1987-11-01), Larm et al.
patent: 4739046 (1988-04-01), DiLuzio et al.
patent: 4761402 (1988-08-01), Williams et al.
patent: 4810646 (1989-03-01), Jamas et al.
patent: 5032401 (1991-07-01), Jamas et al.
patent: 5057503 (1991-10-01), Czop et al.
patent: 5320849 (1994-06-01), Hagiwara et al.
patent: 5322841 (1994-06-01), Jamas et al.
patent: 5488040 (1996-01-01), Jamas et al.
patent: 5532223 (1996-07-01), Jamas et al.
patent: 5622939 (1997-04-01), Jamas et al.
Janusz, M.J. et al., "Isolation of Soluble Yeast .beta.-Glucas That Inhibit Human Monocyte Phagocytosis Mediated by .beta.-Glucan Receptors," J. Immunol. 137: 3270-3276 (Nov. 15, 1986).
Manners, D.J. et al., "The Structure of a .beta.-(1.fwdarw.3)-D-Glucan from Yeast Cell Walls," Biochem. J. 135: 19-30 (1973).
Fleet, G.H., et al., "Isolation and Composition of an Alkali-Soluable Glucan from the Cell Walls of Saccharomyces cerevisiae," Journal of General Microbiology, 94: 180-192 (1976).
Miyazaki, T., et al., "Structural Examination of Antitumour, Water-Soluable Glucans from Grifora umbellata by Use of Four Types of Glucanase," Carbohydrate Research, 65: 235-243 (1978).
Reiskind, J.B. and Mullins, J.T., "Molecular Archiecture of the Hyphal Wall of Achlya ambisexualis Raper. II. Ultrastructural Analyses and a Proposed Model," Can. J. Microbiol., 27: 1100-1105 (1981).
Latge , J.P. et al., "Composition Chimique et Ultrastructure des Parois des Corps Hyphaux et des Azygospores de Conidiobolus obscurus," Can. J. Microbiol., 30: 1507-1521 (1984).
Sherwood, E.R. et al., "Soluable Glucan and Lymphokine-Activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," Chemical Abstracts 108: 179752v (1988).
Hara, C. et al., "A Branched (1.fwdarw.3)-.beta.-D-Glucan from a Water Extract of Dictyophora indusiata FISCH," Carb. Res. 145: 237-346 (1986).
Goldman, R., "Induction of a .beta.-1, 3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid of 1,25-diphydroxyvitamin D.sub.3, " Immunology63:: 319-324 (1988).
Konopski, A. et al., "Phagocytosis of .beta.-1, 3-D-Glucan-Derivatized Microbeads by Mouse Peritoneal Macrophages Involves Three Different Receptors," Scand. J. Immunol. 33: 297-306 (1991).
Williams, D.L. et al., "Development of a Water-Soluble, Sulfated (1.fwdarw.3)-.beta.-D-Glucan Biological Response Modifier Derived from Saccharomyces cerevisiae," Carbohydrate Research 235: 247-257 (1992).
Williams, D.L. et al., "A Sequential Multi-Assay Protocol for the Preclinical Assessment of Natural Product Complex Carbohydrate Immunomodulators," Develop. Biol. Standard, 77: 129-136 (1992).
Williams, D.L. et al., "Development, Physicochemical Characterization and Preclinical Efficacy Evaluation of a Water Soluble Glucan Sulfate Derived from Saccharomyces cerevisiae," Immunopharmacology 22: 139-156 (1991).
Pretus, H.A. et al., "Isolation, Physicochemical Characterization and Preclinical Efficacy Evaluation of Soluble Scleroglucan," The J. of Pharmacol and Exp. Therap. 257:500-510 (1991).
Bacon, J. et al., "The Glucan Components of the Cell Wall of Baker's Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure," Biochem. J. 114: 557-567 (1969).
Vestnik Federalniho Uradu Pro Vynalezy 10: 111 (1989).
Vestnik Federalniho Uradu Pro Vynalezy 11: 122-123 (1989).
Onderdonk, A.B. et al., "Anti-Infective Effect of Poly-.beta.1-6-Glucotrisyl-.beta.1-3-Glucopyranose Glucan In Vivo," Infect. Immun. 60: 1642-1647 (1992).
Abel, G. and J.K. Czop, "Activation of Human Monocyte GM-CSF and TNF-.alpha. Production by Particulate Yeast Glucan," International Congress for Infectious Diseases, Montreal Canada (Abstract), Jul. 15-19, 1990.
Chihara, G. et al., "Lentinan as a Host Defense Potentiator (HPD), " Int. J. Immunotherapy V(4): 145-154 (1989).
Sherwood, E.R. et al., "Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan," Int. J. Immunopharm. 9(3): 261-267 (1987).
Williams, D.L. et al., "Pre-Clinical Safety Evaluation of Soluble Glucan, " Int. J. Immunopharmac. 10(4): 405-414 (1988).
Browder, W. et al., "Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient, " Ann. Surg. pp. 605-613 (1990).
Jamas et al, "A Novel Class of Macrophage-Activating Immunomodulators" ACS Symposium Series, Polymeric Drugs and Delivery Systems, Chapter 5 pp. 44-45 (1991).
Shiota, M. et al., "Comparison of .beta.-Glucan Structures in a Cell Wall Mutant of Saccharomyces cerevisiae and the Wild Type", J. Biochem. 98:1301-1307 (1985).
Jamas et al., "PGG-A Novel Class of Macrophage Activating Immunomodulators", International Congress for Infectious Diseases, Montreal Canada (Abstract), Jul. 15-19, 1990.
Katzen et al., "PGG, A Glucose Polymer, Primes Interleukin-1 and Tumor Necrosis Factor Production . . . ", International Congess for Infectious Diseases, Montreal Canada (Abstract), Jul. 15-19, 1990.
Shah et al., "Influence of PGG on the Phagocytosis of Staphylococcus aureus or Escherichia coli . . . " International Congrss for Infectious Diseases, Montreal Canada (Abstract), Jul. 15-19, 1990.
Onderdonk, A.B., "Effect of a New Carbohydrates Polymer on Survival in a Mouse Model for Experimental E. coli sepsis", International Congress for Infectious Diseases, Montreal Canada (Abstract), Jul. 15-19, 1990.
A. Arbo and J.I. Santos, "Effect of PGG on Neutrophil (PMN) Function in Experimental Malnutrition", International Congress for Infectious Diseases, Montreal Canada (Abstract), Jul. 15-19, 1990.
Onderdonk et al., "Protective Effect of a New Carbohydrate Polymer in a Rat Model for Experimental Intraabdominal Sepsis", First International Congress on Biological Response Modifiers, (Abstract) Quebec Canada, Mar. 22-14, 1991.
P.H. Lagrange and M. Fourgeaud, "Enhanced Natural Resistance Against Severe Disseminated Candida albicans . . . ", Int'l J. of Experimental and Clin. Chemotherapy 4(1):48-55 (1991).
Sakurai et al., "Intravenously Administered (1.fwdarw.3)-.beta.-D-Glucan, SSG, Obtained from Sclerotinia s sclerotiorum IFO 9395 . . . ", Chem. Pharm. Bull. 40(8):2120-2124 (1992).
Jamas et al., "PGG-A Novel Class of Macrophage Activating Immunomodulators", Polymer Preprints 31:194-195, Aug. 8, 1990.
Easson, Jr. D. Davidson
Jamas Spiros
Ostroff Gary R.
Alpha-Beta Technology, Inc.
Kight John
White Everett
LandOfFree
Underivatized, aqueous soluable .beta.(1-3) glucan, composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Underivatized, aqueous soluable .beta.(1-3) glucan, composition , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Underivatized, aqueous soluable .beta.(1-3) glucan, composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-77197